NCT00926055

Effects on Atherosclerosis Regression of Ezetimibe or Ezetimibe Plus Simvastatin; Evaluated by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)

Effects on Atherosclerosis Regression of Ezetimibe Monotherapy or Ezetimibe Plus Simvastatin Combination Therapy: Evaluation by Fluorodeoxyglucose Positron Emission Tomography

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Korea University · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Accepted

Summary

18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques. Therefore, in this study the investigators intend to compare the effect of ezetimibe monotherapy or ezetimibe plus statin combination therapy on the atherosclerosis regression using FDG-PET.

Conditions

• Atherosclerosis

Interventions

Type	Name	Description
DRUG	Ezetrol (Ezetimibe)	Ezetrol - 10 mg once daily for 3 months
DRUG	Vytorin (Ezetimibe + Simvastatin)	Vytorin - 10/20 mg once daily for 3 months

Timeline

• Start date: 2011-09-01
• Primary completion: 2012-09-01
• First posted: 2009-06-23
• Last updated: 2015-03-18

Locations

1 site across 1 country: South Korea